Most Read Articles
Rachel Soon, 03 Apr 2019

The Malaysian Community Pharmacy Guild (MCPG) has submitted a seven-point proposal for comprehensively including community pharmacists (CPs) in the national healthcare system.

14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Rachel Soon, 21 hours ago

Many patient-facing healthcare professionals are supported by colleagues in the back room who make sure they stay well-supplied. For its May-June 2019 issue, MIMS Pharmacist speaks to Choong Kin Hoe, former logistics pharmacist at Hospital Kuala Lumpur (HKL), about what goes on in the store pharmacy.

Pitavastatin superior to other statins for preventing diabetes in AMI patients

08 Oct 2018

Moderate-intensity pitavastatin appears to lower the incidence rate of new-onset diabetes mellitus (NODM) in acute myocardial infarction (AMI) patients, a recent study reports.

Researchers enrolled 2,001 AMI patients without diabetes mellitus, of whom 1,267 received atorvastatin (mean age 64.4±12.5 years; 76.6 percent male), 960 received rosuvastatin (mean age 63.2±12.4 years; 76.1 percent male) and 255 were given pitavastatin (mean age 63.4±12.0 years; 72.2 percent male). The cumulative NODM incidence was evaluated across the different groups.

Kaplan-Meier curves showed that the 3-year cumulative incidence rate of NODM was significantly lower in the pitavastatin group than in the atorvastatin and rosuvastatin groups (3.0 percent vs 8.4 percent and 10.4 percent; p=0.001).

Multivariate Cox regression analysis further provided proof for this association, showing that the type of statin taken was an important prognostic factor for NODM. Those who received atorvastatin (hazard ratio [HR], 2.6; 95 percent CI, 1.163–5.879; p=0.0201) or rosuvastatin (HR, 3.9; 1.756–8.689; p=0.0008) were significantly more likely to develop NODM than those who were given pitavastatin.

Notably, atorvastatin was superior to rosuvastatin in terms of NODM prognosis (HR, 0.669; 0.456–0.982; p=0.0401).

Other significant risk factors included triglyceride (HR, 1.004; 1.003–1.006; p<0.0001) and glucose (HR, 1.006; 1.003-1.008; p<0.0001) levels.

“The present study is the first study that evaluated the effect of statin type on NODM incidence in patients with AMI and compared diabetogenic effect among different same intensity statin therapies,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 03 Apr 2019

The Malaysian Community Pharmacy Guild (MCPG) has submitted a seven-point proposal for comprehensively including community pharmacists (CPs) in the national healthcare system.

14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Rachel Soon, 21 hours ago

Many patient-facing healthcare professionals are supported by colleagues in the back room who make sure they stay well-supplied. For its May-June 2019 issue, MIMS Pharmacist speaks to Choong Kin Hoe, former logistics pharmacist at Hospital Kuala Lumpur (HKL), about what goes on in the store pharmacy.